Clinical Trials Logo

Retinitis clinical trials

View clinical trials related to Retinitis.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06275620 Enrolling by invitation - Clinical trials for X-Linked Retinitis Pigmentosa

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

Start date: November 14, 2023
Phase: Phase 2
Study type: Interventional

This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a full-length AAV vector-based gene therapy targeting RPGR protein.

NCT ID: NCT06162585 Enrolling by invitation - Clinical trials for Retinitis Pigmentosa

Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study

REMAIN
Start date: December 8, 2023
Phase:
Study type: Observational

This study will be conducted following Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) guidelines. Eligible subjects will be consented to return for scheduled study visits for this study following their completion in study NTXMCO-002 (RESTORE). They will not receive a second treatment with MCO-010 (or a repeated sham injection) in this study

NCT ID: NCT05921162 Enrolling by invitation - Clinical trials for Retinitis Pigmentosa

A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection

EXTEND
Start date: July 14, 2023
Phase:
Study type: Observational

This study "A Long-Term Follow-Up Study in Subjects Who Received an Adeno-Associated Viral Vector Serotype 2 Containing the Multi-Characteristic Opsin Gene (vMCO-I) Administered Via Intravitreal Injection" is an observational study and will be conducted following Good Clinical Practice (GCP)- International Conference on Harmonization (ICH) guidelines. Eligible subjects satisfying all inclusion and none of the exclusion criteria will be enrolled. All subject who completed the parent clinical study (NSCT/CT/18/01) will undergo safety and efficacy assessments up to 5 years post study drug injection

NCT ID: NCT05786287 Enrolling by invitation - Clinical trials for Retinitis Pigmentosa

Long-term Safety of UC-MSC Transplantation in Patients With Retinitis Pigmentosa

Start date: July 1, 2023
Phase:
Study type: Observational

The study will perform to follow-up UC-MSCs and CM transplantation. 18 patients will be called back to be examined after 5 years of UC-MSC and/or CM transplantation.

NCT ID: NCT05158049 Enrolling by invitation - Clinical trials for Retinitis Pigmentosa

Longitudinal Study of a Bionic Eye

Start date: December 9, 2021
Phase:
Study type: Observational

This is a longitudinal observational study with participants who have been implanted with the suprachoroidal retinal prosthesis.

NCT ID: NCT03772938 Enrolling by invitation - Clinical trials for Retinitis Pigmentosa

Stem Cells Therapy in Degenerative Diseases of the Retina

Start date: December 13, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and effectiveness of an autologous bone marrow-derived stem/progenitor cells administered intravitreously in the subjects with degenerative diseases of the retina.

NCT ID: NCT03584165 Enrolling by invitation - Choroideremia Clinical Trials

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

SOLSTICE
Start date: June 4, 2018
Phase: Phase 3
Study type: Interventional

The objective of the study is to evaluate the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111 and who have exited an antecedent study; these treated participants will be compared with untreated control participants who have exited the STAR (NCT03496012) study and BIIB112 in participants with X-linked retinitis pigmentosa (XLRP) who have been previously treated with BIIB112 and who have exited an antecedent study.

NCT ID: NCT02804360 Enrolling by invitation - Clinical trials for Retinitis Pigmentosa

Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study

Start date: January 2015
Phase: Phase 2
Study type: Interventional

Purpose: Cystoid macular edema (CME) in retinitis pigmentosa (RP) has been managed in several ways with little success. The aim of our study was to report the use of intravitreal dexamethasone implant in a large series of patients with RP and CME. Setting: Retrospective case series. Methods: Cases were diagnosed as RP based on the classic fundus triad of bone-spicule pigment deposits (intraretinal pigmentary migration), retinal vessel attenuation, waxy pallor of the optic disc along with night blindness and attenuated ERG amplitudes (delays in rod or cone b-wave implicit times). Family history of RP and family screening for RP were important in establishing the diagnosis in eyes with some diagnostic challenge. CME was diagnosed by intravitreous fluorescein angiography IVFA and spectral domain optical coherence tomography (SD-OCT). BCVA was monitored using Snellen visual acuity chart and CME was monitored by SD-OCT on follow-up visits.

NCT ID: NCT02759952 Enrolling by invitation - Clinical trials for Retinitis Pigmentosa

Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial

Start date: January 2013
Phase:
Study type: Observational

Mutations in the PDE6A gene - encoding the -subunit of the rod cGMP-phosphodiesterase - account for 1% of autosomal recessive retinitis pigmentosa (arRP) through impaired regulation of cGMP levels in the rod outer segment. This study aims for a detailed clinical characterization of patients with PDE6A mutations in preparation of a clinical gene replacement study (phase I/II safety trial).